Pharma BD Deal Intelligence
A $25M-upfront, $550M-potential co-development bet on TH-302 that ended in double failure: both the SARC021 sarcoma and MAESTRO pancreatic cancer Phase 3 trials missed statistically significant overall survival, and Merck walked away.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →FDA granted fast-track designation to evofosfamide for advanced pancreatic cancer, validating the hypoxia-activated prodrug approach pursued under the Merck…
Merck KGaA, Darmstadt, Germany decided not to pursue evofosfamide further in soft tissue sarcoma and pancreatic cancer following Phase 3 trial failures.
Threshold partnered with Merck KGaA in 2012 in a global license and co-development agreement; Merck abandoned attempts to commercialize evofosfamide in…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Merck Serono (Merck KGaA) and Threshold global agreement to co-develop/commercialize TH-302. $25M upfront plus up to $35M near-term development milestones; $525M total milestone potential ($280M dev/reg + $245M sales). Merck pays 70% of worldwide development costs.
14K US cases/yr
Soft tissue sarcomas are a heterogeneous group of rare malignancies arising from connective tissues (fat, muscle, nerves, blood vessels). Advanced/metastatic disease is hard to treat: chemotherapy options are limited, response durations are short, and many subtypes are chemoresistant due to tumor hypoxia.
At deal time (2012), front-line metastatic STS treatment was dominated by anthracycline-based chemotherapy (doxorubicin) with or without ifosfamide, plus second-line agents like Yondelis (trabectedin), Votrient (pazopanib, approved 2012), and Halaven (eribulin, approved 2016 for liposarcoma). Evofosfamide (TH-302) was positioned as a hypoxia-activated prodrug delivering bromo-isophosphoramide mustard selectively to oxygen-starved tumor cells, intended as add-on to doxorubicin to deepen response without compounding systemic toxicity. The Merck KGaA/Threshold deal validated hypoxia-targeting as a credible commercial strategy at a time when STS pipelines were thin. The Phase 3 SARC021 trial (640 patients) randomized doxorubicin +/- evofosfamide and read out in 2016 with no statistically significant overall survival benefit, leading Merck KGaA to discontinue STS development per Genetic Engineering & Biotechnology News. The failure left the STS landscape effectively unchanged and reinforced Yondelis and Votrient as standard later-line options.
Pancreatic adenocarcinoma is one of the deadliest solid tumors, with hypoxic, stroma-dense tumor biology that resists chemotherapy. The MAESTRO Phase 3 trial tested evofosfamide + gemcitabine in advanced disease.
Standard 2012 first-line metastatic pancreatic cancer therapy was gemcitabine monotherapy or FOLFIRINOX, with Abraxane (nab-paclitaxel) + gemcitabine emerging in 2013. Evofosfamide was tested on top of gemcitabine in MAESTRO (693 patients) but failed to show statistically significant OS improvement, leading Merck KGaA to discontinue development in December 2015. The deal failure preserved the gemcitabine/Abraxane and FOLFIRINOX status quo and reinforced skepticism about hypoxia-targeting strategies in pancreatic disease.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck KGaA / Threshold Pharmaceuticals, Inc. (this deal) | 2012 | $550M | — |
| Merck KGaA / Millipore Corporation | 2010 | $7.2B | 88 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Merck KGaA / Versum Materials | 2019 | $5.8B | 80 |
| Merck KGaA / Serono SA | 2006 | $13.2B | 74 |
| Merck KGaA / SpringWorks Therapeutics | 2025 | $3.4B | 72 |
| Merck KGaA / Debiopharm | 2021 | $1.1B | — |
← Browse all deals · How we score deals
More: 2012 deals · Merck KGaA deals · Oncology deals